Evidence map›Paper›PMID 34708859›Full record

ArticleHistology and histopathology2021

MiR-222-3p promotes the proliferation, migration and invasion of papillary thyroid carcinoma cells through targeting SLC4A4.

Chunying Zhang, Qing Chang, Yaojie Hu, Wang Chang, Xin Guo, Liru Fu, Guoshuai Tang, Chunyou Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Current medicinal chemistry · 2025
    Article
  2. Article
  3. Plasma miRNA-146b-3p, -222-3p, -221-5p, -21a-3p Expression Levels andInternational journal of molecular sciences · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chunying Zhang *Department of Head and Neck, Tangshan Gongren Hospital, Tangshan, China.
Qing Chang *Department of Head and Neck, Tangshan Gongren Hospital, Tangshan, China.
Yaojie HuDepartment of Head and Neck, Tangshan Gongren Hospital, Tangshan, China.
Wang ChangDepartment of Head and Neck, Tangshan Gongren Hospital, Tangshan, China.
Xin GuoDepartment of Head and Neck, Tangshan Gongren Hospital, Tangshan, China.
Liru FuNorth China University of Science and Technology, Hebei, China.
Guoshuai TangShanghai Engineering Research Center of Pharmaceutical Translation, Shanghai, China.
Chunyou ChenDepartment of Head and Neck, Tangshan Gongren Hospital, Tangshan, China. cyyyChen@163.com.
North China University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAn increasing number of studies indicate that miR-222-3p is upregulated in various cancers and can regulate tumor progression. This study aimed to explore the regulatory mechanism of miR-222-3p in papillary thyroid carcinoma (PTC).

methodsTCGA database was used to dig differentially expressed miRNAs and mRNAs in PTC tissue. Relevant references were searched to determine target miRNA. StarBase, TargetScan and miRDB were applied to predict mRNAs that had binding sites with the target miRNA. Then, the mRNAs were intersected with differentially downregulated mRNAs in TCGA to determine the target mRNA. qRT-PCR was exerted to evaluate gene expression of miR-222-3p and SLC4A4 in PTC. Western blot was performed out to evaluate the protein expression of SLC4A4 in PTC cells. CCK-8, wound healing assay and cell invasion assay were undertaken to observe the proliferative, migratory, and invasive abilities of PTC cells. Dual-luciferase assay was employed to test the binding relationship between miR-222-3p and SLC4A4.

resultsMiR-222-3p was highly expressed in PTC while SLC4A4 was lowly expressed. Moreover, miR-222-3p was able to promote the proliferation, invasion, and migration of PTC cells. SLC4A4 was able to reverse these promotive effects of miR-222-3p.

conclusionMiR-222-3p can promote the proliferation, migration and invasion of PTC cells through targeting SLC4A4. MiR-222-3p is expected to be a molecular therapeutic target for PTC patients.

Indexed as

Cell Culture TechniquesCell MovementCell ProliferationDown-RegulationHumansMicroRNAsSodium-Bicarbonate SymportersThyroid Cancer, PapillaryThyroid NeoplasmsUp-RegulationMicroRNAsMIR222, humanSLC4A4 protein, humanSodium-Bicarbonate Symporters

Identifiers

PMID34708859
OpenAlexW3210508485

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.